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Aims: To evaluate the appearance and distribution of matrix metalloproteinase-2 (MMP-2), tissue 
inhibitor of metalloproteinase-2 (TIMP-2) and tissue inhibitor of metalloproteinase-4 (TIMP-4) in 
lesional skin biopsies of psoriasis patients. 
Study Design: Observational study. 
Place and Duration of Study: Institute of Anatomy and Anthropology and Department of 
Infectology and Dermatology, Rīga Stradiņš University, between September 2013 and June 2014. 
Methodology: We included 40 patients (31 men, 9 women; age range 18-70 years) with   
Psoriasis vulgaris, with present characteristic psoriatic eruptions in typical localization sites and no 
treatment received. Skin samples were obtained using routine punch biopsy method. 10 clinically 
healthy skin samples obtained during nevus excision procedure were used as control material. All 











tissue specimens were stained with hematoxylin and eosin and by immunohistochemistry for MMP-
2, TIMP-2 and TIMP-4. The intensity of staining was graded semiquantitatively. Spearman’s rank 
correlation coefficient was calculated. 
Results: In psoriasis patients numerous MMP-2-containing keratinocytes were found in epidermis, 
MMP-2 positive dermal fibroblasts and inflammatory cells varied from few to abundant. Few 
epidermal cells and moderate to numerous dermal cells contained TIMP-2. Moderate to numerous 
epidermal and dermal cells contained TIMP-4. Statistically significant strong positive correlation 
was found between MMP-2 in epidermis and dermis (Spearman’s rank correlation coefficient = 
.878, P = .000). Statistically significant moderate positive correlation was found between TIMP-2 
and TIMP-4 in dermis (Spearman’s rank correlation coefficient = .639, P = .000) and between 
TIMP-2 in epidermis and dermis (Spearman’s rank correlation coefficient = .564, P = .000). 
Conclusion: TIMP-4 seems to be most important inhibitor of psoriatic skin degeneration, richly 
raised by MMP-2. Its moderate correlation with TIMP-2 proves involvement of other tissue 
inhibitors in the degeneration inhibition and gives evidence about possible patterning between the 
tissue inhibitors of metalloproteinases. 
 
 




Psoriasis is common chronic inflammatory skin 
condition associated with significant 
comorbidities [1]. Genetic and immunologic 
studies suggest psoriasis is a T helper 1-type 
disease. The knowledge about the involvement 
and role of matrix metalloproteinases (MMPs) 
and their tissue inhibitors (TIMPs) in psoriatic 
inflammation is limited. Endogenous and 
exogenous proteases (cathepsins, caspases, 
kallikreins, matriptase) are able to target defense 
molecules in epidermis. At the same time their 
inhibitors maintain the integrity and protective 
barrier of human skin, and it is therefore 
speculated that a misbalance can result in 
inflammation [2]. 
  
The matrix metalloproteinase (MMP) family 
consists of a number of Zinc-dependent 
proteolytic enzymes. MMPs take part in the 
normal development of the skin, but healthy skin 
does not constitutively express MMPs. In 
contrast, MMP-1, MMP-2, MMP-3, MMP-7, 
MMP-8, MMP-9, MMP-12 and membrane type 1-
matrix metalloproteinase (MT1-MMP) degrade 
extracellular matrix in arthritis, hypertension, and 
cardiac disease [3]. Excessive MMPs activity has 
been found in chronic wounds and impaired 
wound healing [4,5]. 
 
MMPs expression in skin is regulated by 
cytokines, growth factors and also the presence 
of tissue inhibitors of metalloproteinases. These 
inhibitors may be multifunctional and can directly 
regulate cell growth and apoptosis. TIMPs have 
also shown the ability to regulate MMPs activity, 
as unregulated MMPs possibly result in tissue 
damage [6]. 
Therefore, we suggest that MMPs and TIMPs 
could be of importance in the pathogenesis of 
psoriasis and should be explored as possible 
biomarkers. The aim of the study was to evaluate 
the appearance and distribution of matrix 
metalloproteinase-2 (MMP-2), tissue inhibitor of 
metalloproteinase-2 (TIMP-2) and tissue inhibitor 
of metalloproteinase-4 (TIMP-4) in lesional skin 




Forty Psoriasis vulgaris patients between the age 
of 18 and 70 (31 men, 9 women) were selected. 
Patients had at least a six weeks history of 
characteristic psoriatic eruptions in typical 
localization sites. Patients with systemic 
comorbidities were excluded. Skin biopsies were 
obtained from new untreated psoriasis lesions 
using routine 3 mm punch biopsy under local 
infiltrative anesthesia using 2% lidocaine, 
maintaining an aseptic technique. Non-lesional 
skin was not studied. Ten clinically healthy skin 
samples obtained during nevus excision 
procedure were used as control material. 
 
Skin biopsy tissue was fixed in Stefanini’s 
solution [7], dehydrated and embedded in 
paraffin. Further four micrometers thick sections 
were prepared and stained routinely with 




Immunohistochemistry (IMH): MMP-2 (Cat No 
AF902, Lot No DUB03, obtained from goat, 
1:100 dilution, R&D Systems, Germany), TIMP-2 
(3A4: sc-21735, obtained from mouse, 1:50 
dilution, Santa Cruz Biotechnology, Inc., USA) 











rabbit, 1:50 dilution, Biorbyt Limited, Cambridge, 
UK) were used by biotin – streptavidin IMH [9]. 
 
Skin biopsy tissue was deparaffinized and 
washed in alcohol and water, then washed for 10 
minutes in wash buffer (Tris-buffered saline) and 
put for 5 minutes in EDTA boiling buffer in 
microwave. When the samples had cooled down, 
they were washed twice for 5 minutes in wash 
buffer. To decrease background staining normal 
blocking serum for 20 minutes was used. All skin 
tissue samples were incubated with primary 
antibodies for 1 hour. Further, washing for 10 
minutes in wash buffer and incubation for 30 
minutes with LSAB+LINK with biotin related 
secondary antibodies (code K1015, 
DakoCytomation, Denmark) was performed. 
Another washing for 5 minutes in wash buffer 
was performed. Skin biopsies were incubated for 
25 minutes with LSAB+LINK with enzyme 
peroxidase labeled streptavidine (code K0690, 
DakoCytomation, Denmark). It was followed by 5 
minutes washing in wash buffer and 10 minutes 
processing with DAB substrate-chromogen 
system (code K3468, DakoCytomation, 
Denmark) to obtain positive structure staining in 
brown colour. Samples were then rinsed in 
running water and stained with hematoxylin.   
 
Findings were evaluated using Leica DC 300F 
camera and image processing and analysis 
software Image Pro Plus. 
 
The intensity of immunostaining was graded 
semiquantitatively:  
 
 Few positive structures in the visual field 
were labeled with +,  
 Moderate number of positive structures in 
the visual field was labeled with ++,  
 Numerous positive structures in the visual 
field were labeled with +++,  
 Abundance of positive structures in the 
visual field was marked with ++++ [10]. 
 
To obtain statistical data we used non-parametric 
statistics – Spearman’s rank correlation 
coefficient was calculated [11]. 
 




In all 10 skin samples obtained from control 
patients we found practically unchanged 
histological picture.  
Lesional epidermis of psoriasis patients was 
characterized by excess proliferation of basal 
layer, prominent reduction of granular layer, 
parakeratosis. Inflammatory infiltration presented 
diffusive character predominantly patchy in 
papillary dermis, especially perivascularly to 
arterioles. We detected presence of numerous 
epitheloid cells and macrophages, as well as 
Munro microabscesses. Inflammatory cells 
(lymphocytes and macrophages mainly) were 
found also surrounding hair follicles and eccrine 





MMP-2 expressed in few to moderate (+/++) 
keratinocytes and in moderate to numerous 
(++/+++) dermal connective tissue cells in 
healthy skin (Fig. 1). In tissue samples of 
psoriasis patients numerous (+++) MMP-2-
containing keratinocytes were found in basal and 
spinous layers (Stratum germinativum) of 
epidermis, while granular layer in many skin 
samples simultaneously was lacking any MMP-2 
positive cells. MMP-2 positive dermal fibroblasts 
and inflammatory cells (macrophages and 
lymphocytes) mainly in papillary layer varied from 
few (+) to abundant (++++) (Fig. 2). MMP-2-
containing cells were found also in sebaceous 
and eccrine sweat glands, hair follicles and walls 
of blood vessels. 
 
In control skin tissue samples numerous (+++) 
keratinocytes contained TIMP-2, while only 
moderate (++) TIMP-2-containing connective 
tissue cells were found in dermis (Fig. 3). 
Psoriatic lesions presented with few (+) 
epidermal keratinocytes mostly in basal layer 
containing TIMP-2, meanwhile TIMP-2-
containing fibroblasts, macrophages and 
lymphocytes in dermis varied mainly from 
moderate (++) to numerous (+++) (Fig. 4). Very 
few eccrine sweat glands, hair follicles and blood 
vessels had traces of TIMP-2 presence. 
 
Numerous (+++) TIMP-4-containing keratino-
cytes were found in epidermis of healthy         
skin, while dermis presented with moderate        
to numerous (++/+++) TIMP-4-containing 
fibroblasts (Fig. 5). Moderate (++) to numerous 
(+++) epidermal keratinocytes and fibroblasts, as 
well as macrophages and lymphocytes in dermis 
contained TIMP-4 in tissue samples of psoriasis 
lesions (Fig. 6). In epidermis the presence of 
TIMP-4 positive cells was patchy. 













Fig. 1. Few MMP-2 containing keratinocytes (1) and moderate MMP-2 positive dermal 




Fig. 2. Abundance of MMP-2-containing keratinocytes (1) in epidermis and fibroblasts (2) and 
inflammatory cells (3) in dermis of psoriatic skin. MMP-2 IMH, X 200,  













Fig. 3. Numerous epidermal keratinocytes (1) and moderate connective tissue cells (2) 




Fig. 4. Numerous TIMP-2 positive macrophages (1) and lymphocytes (2) particularly in 
psoriasis affected papillary dermis. TIMP-2 IMH, X 400, scale bar: 3.6 µm 
 
Numerous TIMP-4 containing cells of sebaceous 
glands and eccrine sweat glands, hair follicles 
and blood vessels were found. 
Statistically significant difference between 
patients with psoriasis and control patients was 














Fig. 5. Numerous TIMP-4-containing keratinocytes (1) in epidermis and moderate TIMP-4-




Fig. 6. Numerous TIMP-4 positive keratinocytes (1) and dermal fibroblasts (2), as well as 
macrophages (3) and lymphocytes (4) in psoriatic skin. TIMP-4 IMH, X 400, scale bar: 3.6 µm 
  
In psoriasis patients statistically significant strong 
positive correlation was found between MMP-2 in 
epidermis and dermis (Spearman’s rank 
correlation coefficient = .878, P = .000) and 
statistically significant moderate positive 
correlation was found between TIMP-2 and 
TIMP-4 in dermis (Spearman’s rank correlation 
coefficient = .639, P= .000), and between TIMP-2 
in epidermis and dermis (Spearman’s rank 
correlation coefficient = .564, P = .000). Also in 
psoriasis patients statistically significant weak 











epidermis and dermis (Spearman’s rank 
correlation coefficient = .485, P = .002) and 
between MMP-2 in epidermis and TIMP-2 in 
epidermis (Spearman’s rank correlation 




We found increased expression of MMP-2 in 
psoriatic epidermis, epidermal appendages and 
dermis. This is in agreement with previous 
studies of MMP-2 in psoriasis patients with a 
history of diabetes and allergy compared to 
patients with psoriasis only [12,13]. Thus, our 
data of MMP-2 presence in psoriatic skin 
suggests a more general MMP-2 upregulation. In 
a previous immunohistochemical study, MMP-2 
and MMP-9 were seen to be upregulated in 
psoriatic skin compared to healthy skin, while 
TIMP-1 and TIMP-2 expression decreased [14]. 
While TIMP-1 appeared immunohistochemically 
decreased in psoriatic lesions, data on MMP-12, 
MMP-9, TIMP-1 and TIMP-3 obtained by mRNA 
imply increases of MMPs and TIMP-1 in psoriatic 
dermal infiltrates [15]. We also found more 
decreased expression of TIMP-2 in psoriatic 
epidermis while dermal cells presented with 
moderate amount of TIMP-2 positive cells 
possibly suggesting a compensatory mechanism.  
 
To our knowledge no studies have looked at the 
presence or absence of TIMP-4 in psoriatic 
lesions. We found abundant TIMP-4-containing 
cells in dermal infiltrates, as well as epidermal 
keratinocytes expressed TIMP-4. Expression of 
TIMP-2 and TIMP-4 in psoriatic dermis showed 
positive correlation and can be hypothesised as 
a pattern of compensatory inhibitory factors 
possibly associated with psoriasis. 
 
MMPs and their inhibitors have also been studied 
in the serum of psoriasis and psoriatic arthritis 
patients. It has been suggested that plasma 
transforming growth factor-beta1, TIMP-1, MMP-
1 and interleukin-18 could be used as combined 
biomarker of psoriasis activity [16]. Plasma 
MMP-3 together with high-sensitivity C-reactive 
protein might help to differentiate psoriatic 
disease alone from psoriasis together with 
psoriatic arthritis [17]. Changes in plasma 
concentrations of MMP-1 and TIMP-1 levels in 
psoriasis patients have been detected as a 
response to topical psoriasis treatment [18]. 
The data are compatible with decreased 
epidermal regulation of MMP-2 and a 
compensatory increase in dermal TIMP 
expression. In contrast to the increased 
expression of MMP-2, the observations imply 
that the role and expression of TIMP is 
controversial and can show differences between 
gene involvement and tissue findings. We 
suggest that an MMP-2 increase along to TIMP-2 
and TIMP-4 correlative changes could serve as 
tissue biopattern for the psoriasis, suggesting a 




TIMP-4 seems to be most important inhibitor of 
psoriatic skin degeneration, richly raised by 
MMP-2. Its moderate correlation with TIMP-2 
proves involvement of other tissue inhibitors in 
the degeneration inhibition and gives evidence 
about possible patterning between the tissue 




It is not applicable. 
 
ETHICAL APPROVAL  
 
All authors hereby declare that all experiments 
have been examined and approved by the 
appropriate ethics committee and have therefore 
been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of 
Helsinki. 
 
The study was approved by the Ethical 
Committee at Rīga Stradiņš University, permit 




‘‘Support for Doctoral Students in Mastering the 
Study Programme and Acquisition of a Scientific 










1. Miller IM, Ellervik C, Zarchi KS, Ibler KS, 
Vinding GR, Knudsen KM, et al. The 
association of metabolic syndrome and 











cross-sectional study. J Eur Acad Dermatol 
Venereol. 2015;29(3):490-7.  
(DOI: 10.1111/jdv.12595) 
2. Meyer-Hoffert U. Reddish, scaly, and itchy: 
how proteases and their inhibitors 
contribute to inflammatory skin diseases. 
Arch Immunol Ther Exp (Warsz). 
2009;57(5):345-54.  
(DOI: 10.1007/s00005-009-0045-6) 
3. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, 
Zhang L. Matrix metalloproteinases: 
Inflammatory regulators of cell behaviors in 
vascular formation and remodeling. 
Mediators Inflamm. 2013;928315.  
DOI: 10.1155/2013/928315 
4. Raza SL, Cornelius LA. Matrix 
metalloproteinases: Pro- and anti-
angiogenic activities. J Investig Dermatol 
Symp Proc. 2000;5(1):47-54. 
5. Xue M, Le NT, Jackson CJ. Targeting 
matrix metalloproteases to improve 
cutaneous wound healing. Expert Opin 
Ther Targets. 2006;10(1):143-55.  
(DOI: 10.1517/14728222.10.1.143) 
6. Stetler-Stevenson WG. Tissue inhibitors of 
metalloproteinases in cell signaling: 
Metalloproteinase-independent biological 
activities. Sci Signal. 2008;1(27):re6.  
(DOI: 10.1126/scisignal.127re6) 
7. Stefanini M, De Martino C, Zamboni L. 
Fixation of ejaculated spermatozoa for 
electron microscopy. Nature. 1967;216 
(5111):173-4. 
8. Fischer AH, Jacobson KA, Rose J, Zeller 
R. Hematoxylin and eosin staining of tissue 
and cell sections. CSH Protoc. 2008; 
pdb.prot4986.  
(DOI: 10.1101/pdb.prot4986) 
9. Hsu SM, Raine L, Fanger H. The use of 
antiavidin antibody and avidin-biotin 
peroxidase complex in immunoperoxidase 
technics. Am J Clin Pathol. 1981;75(6): 
816-21. 
10. Pilmane M, Luts A, Sundler F. Changes in 
neuroendocrine elements in bronchial 
mucosa in chronic lung disease in adults. 
Thorax. 1995;50(5):551-4. 
11. Christensen R. Analysis of Variance, 
Design and Regression: Applied Statistical 
Methods. London: Chapman & Hall; 1996. 
12. Lee SE, Lew W. The Increased Expression 
of Matrix-Metalloproteinase-9 Messenger 
RNA in Non-lesional Skin of Patients with 
Large Plaque Psoriasis Vulgaris. Ann 
Dermatol. 2009;21(1):27-34.  
(DOI: 10.5021/ad.2009.21.1.27) 
13. Vasku V, BienertovaVasku J, Slonková V, 
Kanková K, Vasku A. Matrix 
metalloproteinase-2 promoter variability in 
psoriasis. Arch Dermatol Res. 2009;301 
(6):467-73.  
(DOI: 10.1007/s00403-009-0947-5) 
14. Simonetti O, Lucarini G, Goteri G, Zizzi A, 
Biagini G, Lo Muzio L et al. VEGF is likely 
a key factor in the link between 
inflammation and angiogenesis in 
psoriasis: Results of an 
immunohistochemical study. Int J 
Immunopathol Pharmacol. 2006;19(4):   
751-60. 
15. Suomela S, Kariniemi AL, Snellman E, 
Saarialho-Kere U. Metalloelastaze (MMP-
12) and 92-kDa gelatinase (MMP-9) as 
well as their inhibitors, TIMP-1 and -3, are 




16. Flisiak I, Zaniewski P, Chodynicka B. 
Plasma TGF-beta1, TIMP-1, MMP-1 and 
IL-18 as a combined biomarker of psoriasis 
activity. Biomarkers. 2008;13(5):549-56. 
17. Chandran V. Soluble biomarkers may 
differentiate psoriasis from psoriatic 
arthritis. J Rheumatol Suppl. 2012;89:65-6. 
(DOI: 10.3899/jrheum.120247) 
18. Flisiak I, Mysliwiec H, Chodynicka B. Effect 
of psoriasis treatment on plasma 
concentrations of metalloproteinase-1 and 
tissue inhibitor of metalloproteinases-1. J 





© 2015 Sidhom et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
 
 
  Peer-review history: 
The peer review history for this paper can be accessed here: 
http://www.sciencedomain.org/review-history.php?iid=1122&id=12&aid=9506 
 
View publication stats
